

Ruth Van Daele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6392664/publications.pdf>

Version: 2024-02-01

20
papers

378
citations

1307366

7
h-index

794469

19
g-index

20
all docs

20
docs citations

20
times ranked

493
citing authors

#	ARTICLE	IF	CITATIONS
1	Isavuconazole in the Treatment of <i>Aspergillus fumigatus</i> Fracture-Related Infection: Case Report and Literature Review. <i>Antibiotics</i> , 2022, 11, 344.	1.5	3
2	Exposure to intravenous posaconazole in critically ill patients with influenza: A pharmacokinetic analysis of the POSA-FLU study. <i>Mycoses</i> , 2022, 65, 656-660.	1.8	3
3	Concomitant use of isavuconazole and CYP3A4/5 inducers: Where pharmacogenetics meets pharmacokinetics. <i>Mycoses</i> , 2021, 64, 1111-1116.	1.8	3
4	Pharmacokinetic/Pharmacodynamic Target Attainment Based on Measured versus Predicted Unbound Ceftriaxone Concentrations in Critically Ill Patients with Pneumonia: An Observational Cohort Study. <i>Antibiotics</i> , 2021, 10, 557.	1.5	9
5	Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): a randomised, open-label, proof-of-concept trial. <i>Intensive Care Medicine</i> , 2021, 47, 674-686.	3.9	49
6	Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	1
7	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. <i>Microorganisms</i> , 2021, 9, 1543.	1.6	23
8	A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 512-518.	1.0	9
9	Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid. <i>Antibiotics</i> , 2021, 10, 1112.	1.5	5
10	Letermovir exposure in transplant patients with end-stage renal disease on renal replacement therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 3322-3325.	1.3	2
11	Interaction between flucloxacillin and azoles: is isavuconazole next?. <i>Mycoses</i> , 2021, 64, 1508-1511.	1.8	3
12	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1234-1241.	1.3	14
13	Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients. <i>Microorganisms</i> , 2021, 9, 2068.	1.6	8
14	Ultra-performance liquid chromatography for quantification of amphotericin B plasma concentrations after use of liposomal amphotericin B. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 961-966.	1.3	2
15	Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020, 16, 539-550.	1.5	12
16	Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?. <i>Frontiers in Pharmacology</i> , 2020, 11, 620.	1.6	62
17	Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. <i>Medical Mycology</i> , 2020, 58, 874-880.	0.3	8
18	Development and External Validation of an Online Clinical Prediction Model for Augmented Renal Clearance in Adult Mixed Critically Ill Patients: The Augmented Renal Clearance Predictor. <i>Critical Care Medicine</i> , 2020, 48, e1260-e1268.	0.4	14

#	ARTICLE	IF	CITATIONS
19	Antifungal drugs: What brings the future?. <i>Medical Mycology</i> , 2019, 57, S328-S343.	0.3	141
20	Diagnosing Invasive Mold Infections: What Is Next. <i>Current Fungal Infection Reports</i> , 2018, 12, 161-169.	0.9	7